LY-379,268 is a drug that is used in neuroscience research, which acts as a potent and selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).
^Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, et al. (March 1999). "Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors".Journal of Medicinal Chemistry.42 (6):1027–1040.doi:10.1021/jm980616n.PMID10090786.
^Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, et al. (April 2007). "Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)".The Journal of Pharmacology and Experimental Therapeutics.321 (1):308–317.doi:10.1124/jpet.106.110809.PMID17204749.S2CID23666836.
^Cai Z, Xiao F, Fratkin JD, Rhodes PG (December 1999). "Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist".NeuroReport.10 (18):3927–3931.doi:10.1097/00001756-199912160-00037.PMID10716235.
^Moldrich RX, Jeffrey M, Talebi A, Beart PM, Chapman AG, Meldrum BS (July 2001). "Anti-epileptic activity of group II metabotropic glutamate receptor agonists (--)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and (--)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795)".Neuropharmacology.41 (1):8–18.doi:10.1016/S0028-3908(01)00044-2.PMID11445181.S2CID26104177.
^Uys JD, LaLumiere RT (November 2008). "Glutamate: the new frontier in pharmacotherapy for cocaine addiction".CNS & Neurological Disorders Drug Targets.7 (5):482–491.doi:10.2174/187152708786927868.PMID19128205.
^Cartmell J, Monn JA, Schoepp DD (March 2000). "Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine".Psychopharmacology.148 (4):423–429.doi:10.1007/s002130050072.PMID10928316.S2CID22988081.
^Greenslade RG, Mitchell SN (July 2004). "Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell".Neuropharmacology.47 (1):1–8.doi:10.1016/j.neuropharm.2004.02.015.PMID15165829.S2CID25267021.
^Kłodzinska A, Bijak M, Tokarski K, Pilc A (September 2002). "Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice".Pharmacology, Biochemistry, and Behavior.73 (2):327–332.doi:10.1016/S0091-3057(02)00845-6.PMID12117586.S2CID28841684.
^Molinaro G, Traficante A, Riozzi B, Di Menna L, Curto M, Pallottino S, et al. (August 2009). "Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice".Molecular Pharmacology.76 (2):379–387.doi:10.1124/mol.109.056580.PMID19439499.S2CID14722003.
^Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, et al. (December 2004). "The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis".Neuropharmacology.47 (8):1135–1145.doi:10.1016/j.neuropharm.2004.08.018.PMID15567423.S2CID22374384.
^Seeman P, Guan HC (November 2008). "Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia".Synapse.62 (11):819–828.doi:10.1002/syn.20561.PMID18720422.S2CID206519749.
^Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, et al. (December 2009). "In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)".The Journal of Pharmacology and Experimental Therapeutics.331 (3):1126–1136.doi:10.1124/jpet.109.160598.PMID19755662.S2CID23981819.